Physician profile
Michael S Chen
NPI 1184650954
$241,415.47
in general payments reported to CMS, 2019-2025
41 companies · $13K in 2025
The $13K reported for 2025 was more than what 90% of Interventional Cardiology providers received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,250 · 2020: $4,835 · 2021: $14K · 2022: $38K · 2023: $106K · 2024: $56K · 2025: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $121K · Travel and Lodging: $22K · Honoraria: $22K · Food and Beverage: $10K · Education: $116.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $121,430.00 |
| Travel and Lodging | $22,004.14 |
| Honoraria | $21,607.00 |
| Food and Beverage | $10,000.13 |
| Education | $116.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $74,598.36 | 2021-2025 | Verquvo, Capvaxive |
| Lilly USA, LLC | $51,571.12 | 2022-2025 | Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48,617.80 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals Lp | $32,505.63 | 2019-2025 | Farxiga, Brilinta, Lokelma |
| Lexicon Pharmaceuticals, INC. | $23,770.67 | 2023-2024 | Inpefa |
| Novo Nordisk INC | $1,471.99 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Abbott Laboratories | $1,279.90 | 2019-2023 | Thoratec Heartmate 3 Lvas Implant Kit |
| Janssen Pharmaceuticals, INC | $1,202.75 | 2019-2024 | Xarelto |
| Amgen INC. | $1,108.88 | 2019-2025 | Repatha, Repatha |
| E.R. Squibb & Sons, L.L.C. | $911.76 | 2019-2025 | Camzyos, Eliquis |
| Novartis Pharmaceuticals Corporation | $648.12 | 2019-2025 | |
| Amarin Pharma, INC. | $520.81 | 2019-2023 | |
| Esperion Therapeutics, INC. | $496.81 | 2020-2025 | Nexletol |
| Bayer Healthcare Pharmaceuticals INC. | $372.74 | 2022-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $371.27 | 2019-2025 | Lifevest |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $341.31 | 2019-2025 | |
| Boston Scientific Corporation | $174.18 | 2021-2024 | Watchman Access System |
| Kiniksa Pharmaceuticals, Ltd. | $136.38 | 2022-2023 | Arcalyst |
| Scpharmaceuticals INC. | $136.02 | 2023-2025 | |
| Medtronic Vascular, INC. | $125.37 | 2020 | |
| Irhythm Technologies, INC. | $102.54 | 2024 | Zio Monitor, Zio Xt Patch |
| Kowa Pharmaceuticals America, INC. | $102.32 | 2019-2020 | |
| Philips North America LLC | $94.93 | 2019-2024 | (Ck4) Mcot |
| Aerin Medical INC. | $90.57 | 2025 | |
| Sanofi-Aventis U.S. LLC | $86.13 | 2019-2022 | |
| Atricure, INC. | $67.45 | 2022-2024 | |
| Edwards Lifesciences Corporation | $66.21 | 2019 | |
| Daiichi Sankyo INC. | $65.10 | 2021-2025 | Injectafer |
| Regeneron Healthcare Solutions, INC. | $64.57 | 2019 | |
| Baxter Healthcare | $58.21 | 2025 | Hillrom - Carnation Ambulatory Monitor, Hillrom - Cardiac Ambulatory Monitor |
| Cook Medical LLC | $45.56 | 2019 | |
| Gilead Sciences, INC. | $36.49 | 2019 | |
| Medtronic, INC. | $35.17 | 2023 | Symplicity G3 |
| Glaxosmithkline, LLC. | $25.85 | 2025 | Shingrix |
| Bridgebio Pharma, INC. | $22.02 | 2025 | Attruby |
| Kiniksa Pharmaceuticals International, Plc | $19.17 | 2024 | Arcalyst |
| Abiomed | $18.81 | 2024 | Impella |
| Inari Medical, INC. | $16.55 | 2021 | |
| Lundbeck LLC | $14.07 | 2021 | |
| Allergan, INC. | $11.44 | 2019 | |
| Bardy Diagnostics, INC. | $10.44 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.